Survival Monitoring in Russian Cancer Registries (SURVIMON)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06043947 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 21, 2023
Last Update Posted : October 16, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease |
|---|
| Melanoma Breast Cancer Oncology Colon Cancer Prostate Cancer Survivorship Lung Cancer Cervix Cancer |
The main sources of cancer incidence data in Russia are population-based cancer registries (PBCR). National recommendations guide the content of corresponding variables stored in PBCRs. Data were collected for the following regions: Arkhangelsk Oblast and Nenets Autonomous Okrug (combined), Republic of Karelia, Komi Republic, Vologda Oblast, Kaliningrad Oblast, Leningrad Oblast, Murmansk Oblast, Novgorod Oblast, Pskov Oblast, and St. Petersburg. Quality assessment procedures will be applied to the population-based cancer registries (PBCRs) datasets. Essential variables will be extracted following the recommended list of ENCR/IACR.
The list of variables consists of two classes: original variables present in PBCRs datasets and synthetic variables calculated based on the original variables. "IARC/IACR Tools for Cancer Registries" (IARC tools) software was used for the data cleaning, conversion to ICD-O-3, and multiple primaries assessment. Duplicates were removed by applying IARC/IACR/ENCR multiple primary rules. The analysis is limited to twenty years: 2000 - 2021.
The Federal State Statistics Service (FSSS) is the primary regional and national mortality data source. However, the raw data from this source has several drawbacks. The main problem is the absence of the distribution of persons with undetermined ages and/or causes of death. The data sets for this research are obtained from the Russian Fertility and Mortality Database (RFMD) of the Center for Demographic Research of the New Economic School. The RFMD database is based on the FSSS data but has a higher data quality due to the redistribution of deaths with the abovementioned characteristics. This source's population and mortality data contained the following variables: region, year, sex, age (5-year age groups from 0 to 85+), and cause of death.
Population data was obtained from the same source. The data were based on the 1989, 2002 and 2010 population censuses. It has been extrapolated to other years using annual statistics on mortality and births.
| Study Type : | Observational [Patient Registry] |
| Estimated Enrollment : | 100000 participants |
| Observational Model: | Cohort |
| Time Perspective: | Other |
| Target Follow-Up Duration: | 10 Years |
| Official Title: | Survival Monitoring in Russian Cancer Registries |
| Actual Study Start Date : | August 1, 2023 |
| Estimated Primary Completion Date : | December 31, 2023 |
| Estimated Study Completion Date : | January 31, 2024 |
- Net survival [ Time Frame: From the date of diagnosis to the date of death (up to 10 years) ]Net survival computed using Pohar-Perme method.
- Cause-specific survival [ Time Frame: From the date of diagnosis to the date of death (up to 10 years) ]Rates calculated using Kaplan-Maier method.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 0 Years to 100 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Men and women of any age
- Data record meets IARC/IACR Tools for Cancer Registries requirements
Exclusion Criteria:
- Severe patient data missing from a record
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06043947
| Russian Federation | |
| N. N. Petrov Research Institute of oncology | |
| Saint-Petersburg, Russian Federation, 197758 | |
| Responsible Party: | N.N. Petrov National Medical Research Center of Oncology |
| ClinicalTrials.gov Identifier: | NCT06043947 |
| Other Study ID Numbers: |
SURVIMON-2023 |
| First Posted: | September 21, 2023 Key Record Dates |
| Last Update Posted: | October 16, 2023 |
| Last Verified: | August 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Survivorship survey Survivorship care Oncology |
Melanoma Breast cancer Lung cancer |
|
Melanoma Uterine Cervical Neoplasms Neoplasms by Site Neoplasms Skin Diseases Urogenital Neoplasms Genital Diseases Urogenital Diseases Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Uterine Neoplasms Genital Neoplasms, Female Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications |